Physician profile
Rajan Sood
NPI 1801873898
$2,247.90
in general payments reported to CMS, 2019-2025
17 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2020: $386 · 2021: $322 · 2022: $227 · 2023: $636 · 2024: $225 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $974.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $904.51 | 2019-2023 | Fanapt, Hetlioz |
| Boston Scientific Corporation | $538.08 | 2023-2024 | Embold Fibered, Obsidio |
| Novo Nordisk INC | $162.16 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $122.46 | 2020 | |
| Canon Medical Systems USA, INC. | $96.00 | 2023 | Interventional Angiography System |
| Lundbeck LLC | $86.42 | 2025 | Rexulti |
| Almatica Pharma LLC | $80.89 | 2022-2023 | Gralise, Sertraline Hcl |
| Alkermes, INC. | $55.89 | 2022-2023 | Lybalvi |
| Abbvie INC. | $51.33 | 2021-2024 | |
| Corium, LLC | $34.22 | 2023 | Azstarys |
| Organogenesis INC. | $26.73 | 2025 | Cygnus Dual |
| Celgene Corporation | $22.67 | 2024 | Zeposia |
| Noven Therapeutics, LLC | $17.65 | 2022 | |
| Braintree Laboratories, INC. | $14.02 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.93 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $10.83 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $10.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.